SynthesisBMJ global health2026
5-year survival rate and determinants of decreased survival among patients with breast cancer in Africa: a systematic review and meta-analysis.
Synthesis in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is the most commonly diagnosed cancer among women worldwide and a leading cause of cancer-related mortality. Survival varies across regions, with most deaths occurring in low- and middle-income countries due to limited early detection and treatment access. This study aimed to estimate the 5-year survival rate and identify determinants of decreased survival among patients with breast cancer in Africa.
methodsA systematic review of only retrospective cohort studies was conducted using PubMed, Hinari, EMBASE, Google Scholar, African Journals Online, African Index Medicus and Web of Science. The literature search was conducted for a 1-month duration (1-30 November 2024). We included all available articles without restriction on publication date to ensure a comprehensive review. Methodological quality was assessed using the Newcastle-Ottawa 2016 Critical Appraisal Checklist. Publication bias was evaluated using funnel plots and Egger's test, and heterogeneity was assessed with the I
results55 articles with 19 577 participants from 19 countries were included; 37 studies (4622 participants) were used to estimate pooled 5-year survival. The pooled 5-year survival rate of patients with breast cancer in Africa was 40.38% (95% CI 33.92 to 46.83%). Reduced survival was strongly associated with tumour characteristics, including tumour stage >2 (HR 3.06, 95% CI 2.02 to 4.09), negative oestrogen receptor status (HR 2.52, 95% CI 1.89 to 3.15), tumour size >5 cm (HR 1.62, 95% CI 1.48 to 1.76), positive nodal status (HR 1.64, 95% CI 1.58 to 1.70) and higher histological grade (HR 1.26, 95% CI 1.22 to 1.29). Treatment-related factors such as single-agent chemotherapy (HR 1.78, 95% CI 1.04 to 2.53) and patient-related factors, including comorbidities (HR 1.45, 95% CI 1.40 to 1.50) and illiteracy (HR 6.54, 95% CI 4.39 to 8.69), were also associated with reduced survival.
conclusionThis study reveals a critically low 5-year survival rate of 40.4% for breast cancer in Africa. Poor survival is linked to advanced tumour features, suboptimal treatment and patient-related factors, with comorbidities and illiteracy being the strongest patient-related factors. These results highlight the urgent need for integrated strategies focused on early diagnosis, public education, equitable access to multimodal therapies and systematic management of comorbidities across the continent. PROSPERO REGISTRATION NUMBER: CRD420261387399.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.